MAPT and Alzheimer disease: We propose a “two‐hit model” to explain the pathological manifestations associated with AD/PD where both age‐ and Tau/Synuclein‐driven metabolic reprogramming events cooperate with each other and targeting both could be a potent therapeutic strategy.